HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

EROSION III: A Multicenter RCT of OCT-Guided Reperfusion in STEMI With Early Infarct Artery Patency.

AbstractOBJECTIVES:
The aim of this study was to test whether optical coherence tomographic (OCT) guidance would provide additional useful information beyond that obtained by angiography and lead to a shift in reperfusion strategy and improved clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) with early infarct artery patency.
BACKGROUND:
Angiography is limited in assessing the underlying pathophysiological mechanisms of the culprit lesion.
METHODS:
EROSION III (Optical Coherence Tomography-Guided Reperfusion in ST-Segment Elevation Myocardial Infarction With Early Infarct Artery Patency) is an open-label, prospective, multicenter, randomized, controlled study approved by the ethics committees of participating centers. Patients with STEMI who had angiographic diameter stenosis ≤ 70% and TIMI (Thrombolysis In Myocardial Infarction) flow grade 3 at presentation or after antegrade blood flow restoration were recruited and randomized to either OCT guidance or angiographic guidance. The primary efficacy endpoint was the rate of stent implantation.
RESULTS:
Among 246 randomized patients, 226 (91.9%) constituted the per protocol set (112 with OCT guidance and 114 with angiographic guidance). The median diameter stenosis was 54.0% (IQR: 48.0%-61.0%) in the OCT guidance group and 53.5% (IQR: 43.8%-64.0%) in the angiographic guidance group (P = 0.57) before randomization. Stent implantation was performed in 49 of 112 patients (43.8%) in the OCT group and 67 of 114 patients (58.8%) in the angiographic group (P = 0.024), demonstrating a 15% reduction in stent implantation with OCT guidance. In patients treated with stent implantation, OCT guidance was associated with a favorable result with lower residual angiographic diameter stenosis (8.7% ± 3.7% vs 11.8% ± 4.6% in the angiographic guidance group; P < 0.001). Two patients (1 cardiac death, 1 stable angina) met the primary safety endpoint in the OCT guidance group, as did 3 patients (3 cardiac deaths) in the angiographic guidance group (1.8% vs 2.6%; P = 0.67). Reinfarction was not observed in either group. At 1 year, the rates of predefined cardiocerebrovascular events were comparable between the groups (11.6% after OCT guidance vs 9.6% after angiographic guidance; P = 0.66).
CONCLUSIONS:
In patients with STEMI with early infarct artery patency, OCT guidance compared with angiographic guidance of reperfusion was associated with less stent implantation during primary percutaneous coronary intervention. These favorable results indicate the value of OCT imaging in optimizing the reperfusion strategy of patients with STEMI. (EROSION III: OCT- vs Angio-Based Reperfusion Strategy for STEMI; NCT03571269).
AuthorsHaibo Jia, Jiannan Dai, Luping He, Yishuo Xu, Yongfeng Shi, Lei Zhao, Zhiqi Sun, Yin Liu, Ziqian Weng, Xue Feng, Dirui Zhang, Tao Chen, Xiling Zhang, Lulu Li, Yousheng Xu, Yanqing Wu, Yining Yang, Chunmei Wang, Lang Li, Jianping Li, Jingbo Hou, Bin Liu, Gary S Mintz, Bo Yu
JournalJACC. Cardiovascular interventions (JACC Cardiovasc Interv) Vol. 15 Issue 8 Pg. 846-856 (04 25 2022) ISSN: 1876-7605 [Electronic] United States
PMID35367176 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
CopyrightCopyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Topics
  • Arteries
  • Constriction, Pathologic (etiology)
  • Coronary Angiography (methods)
  • Humans
  • Myocardial Infarction (diagnostic imaging, etiology, therapy)
  • Percutaneous Coronary Intervention (methods)
  • Prospective Studies
  • Reperfusion
  • ST Elevation Myocardial Infarction (diagnostic imaging, etiology, therapy)
  • Tomography, Optical Coherence (methods)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: